Say Hello to BrainGuide

Our new platform BrainGuide™ was featured on Good Morning America. It empowers people of all ages and communities to understand and take action on brain health and Alzheimer's disease.

Aducanumab and UsAgainstAlzheimer's

Aducanumab is a proposed treatment for early Alzheimer’s disease that is intended to slow the progression of the disease. UsAgainstAlzheimer’s (UsA2) has urged the U.S. Food and Drug Administration to approve aducanumab.

UsAgainstAlzheimer’s Survey Shows Alzheimer’s Patients Value a New Therapy that Slows Progression of Symptoms

New survey results from UsAgainstAlzheimer’s A-LIST shows that patients want FDA to weigh willingness of people with MCI/mild Alzheimer’s to take a disease-modifying therapy.

Paid Leave Alliance for Dementia Caregivers Applauds American Rescue Plan but Urges Action on Paid Leave Support for Caregivers

The Paid Leave Alliance for Dementia Caregivers commends the Biden-Harris for making support for working families a top priority in its $1.9 trillion COVID-19 economic relief proposal but urges the administration to clarify how the proposal's paid leave expansions will cover Americans who care for older adults.

UsAgainstAlzheimer’s Commends Apple and Biogen for New Research on Monitoring Brain Health

UsAgainstAlzheimer’s commends Apple and Biogen for their investment in brain health research and working towards creating innovative technologies that would allow consumers to be more aware and in control of their brain health.

Say Hello to BrainGuide

Aducanumab and UsAgainstAlzheimer's

UsAgainstAlzheimer’s Survey Shows Alzheimer’s Patients Value a New Therapy that Slows Progression of Symptoms

Paid Leave Alliance for Dementia Caregivers Applauds American Rescue Plan but Urges Action on Paid Leave Support for Caregivers

UsAgainstAlzheimer’s Commends Apple and Biogen for New Research on Monitoring Brain Health

UsAgainstAlzheimer's: Working to End Alzheimer's Disease  

The Alzheimer’s pandemic is the health and social economic crisis of this generation. It is a national and global emergency that has a devastating health, social and economic toll on millions of people living with this disease, their families and caregivers.

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. Since our founding in 2010, we have taken on the toughest problems in the fight to end Alzheimer’s. Our work is driven by the urgency to find effective treatments and the prevention steps needed to reach the time where no one is lost to Alzheimer’s.

We bring all of “Us” together to:

In the past decade, progress has been made, with more hope on the horizon now than ever before.

But every day of delay is another day lost to the millions of people affected by this devastating disease. If nothing changes, by 2050, 14 million Americans will be living with Alzheimer’s at an annual cost of more than $1 trillion. The time to act is now.

Recent News and Blog Posts

  • March 18, 2021

    UsAgainstAlzheimer’s Welcomes Confirmation of Xavier Becerra as Secretary of Health and Human Services

    UsAgainstAlzheimer’s issued the following statement by George Vradenburg, chairman and co-founder, on...

    Read more
  • March 15, 2021

    A Year of Stress, Isolation and Decline: New Survey Spotlights Effects of COVID-19 Pandemic on Alzheimer’s Patients and Caregivers

    A new UsAgainstAlzheimer’s A-LIST® survey shows the coronavirus pandemic and related closures...

    Read more
  • March 13, 2021

    UsAgainstAlzheimer’s Statement on Promising Results for Donanemab in Slowing Decline in Early Alzheimer’s Patients

    UsAgainstAlzheimer’s issued the following statement on the release by Eli Lilly of...

    Read more
  • March 08, 2021

    UsAgainstAlzheimer’s Statement on the Retirement Announcement of Sen. Roy Blunt

    “Roy Blunt is a true champion in the fight to stop Alzheimer’s...

    Read more
  • Greg O'Brien

    A Case for FDA Approval: Biogen’s Aducanumab - First-Ever Drug to Slow Progression of Alzheimer’s

    Time kills deals, as the saying goes. And the biggest deal on...

    Read more
  • February 10, 2021

    UsAgainstAlzheimer’s Calls for $289 Million Increase in FY22 Federal Spending for NIH Alzheimer’s Research

    UsAgainstAlzheimer’s released the following statement on the Alzheimer’s community’s recommended $289 million...

    Read more

Reports

  • Resources
    Thumbnail

    A-LIST Pulse of the Community: Volume 7, December 2020

    The UsAgainstAlzheimer’s A-LIST® is an online community of more than 8,000 people living with Alzheimer’s and other dementias, current and former caregivers, and those concerned about brain health, who have...

  • Resources
    Thumbnail

    Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

    The effects of where people live, and the social determinants of health are under-recognized and under-appreciated in our national response to effectively treat and prevent Alzheimer’s. This report found that...

  • Resources
    Thumbnail

    2019 Annual Report

    In these pages, you will find highlights of the game-changing accomplishments and tremendous progress of UsAgainstAlzheimer's and our partners in the year of 2019.